Topic Highlight
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. May 21, 2014; 20(19): 5708-5720
Published online May 21, 2014. doi: 10.3748/wjg.v20.i19.5708
Molecular diagnosis and treatment of drug-resistant hepatitis B virus
Jeong Han Kim, Yong Kwang Park, Eun-Sook Park, Kyun-Hwan Kim
Jeong Han Kim, Digestive Disease Center, Department of Internal Medicine, School of Medicine, Konkuk University, Seoul 143-729, South Korea
Yong Kwang Park, Eun-Sook Park, Kyun-Hwan Kim, Department of Pharmacology and Center for Cancer Research and Diagnostic Medicine, IBST, School of Medicine, Konkuk University, Seoul 143-729, South Korea
Yong Kwang Park, Eun-Sook Park, Kyun-Hwan Kim, Institute of Functional Genomics, Konkuk University, Seoul 143-729, South Korea
Author contributions: All authors contributed to this work.
Supported by Konkuk University
Correspondence to: Kyun-Hwan Kim, Associate Professor, Department of Pharmacology and Center for Cancer Research and Diagnostic Medicine, IBST, School of Medicine, Konkuk University, Gwangjin-gu, Seoul 143-729, South Korea. khkim10@kku.ac.kr
Telephone: +82-2-20307833 Fax: +82-2-20496192
Received: October 27, 2013
Revised: January 29, 2014
Accepted: March 19, 2014
Published online: May 21, 2014
Processing time: 203 Days and 11.6 Hours
Core Tip

Core tip: Although several antiviral agents have been developed in the last two decades for the treatment of chronic hepatitis B (CHB), antiviral resistance remains an important challenge for long-term CHB therapy. In this review, we discussed the currently available molecular diagnosis tools, in vitro phenotypic assays for validation of drug-resistant hepatitis B virus (HBV), and treatment options for drug-resistant HBV.